Aptar Q2 sales beat estimates on strength in consumer healthcare and injectables

Aptar expects third-quarter 2026 adjusted EPS between $1.45 and $1.53.

The company anticipates solid growth across Pharma, Beauty and Closures segments in Q3, and expects the emergency medicine destocking headwind to abate by Q4.

• Pharma segment mix — Growth in consumer healthcare, injectables and prescription applications, partly offset by lower emergency medicine sales and weaker active material science solutions.
• Beauty demand and mix — Increased demand for prestige fragrance dispensing and color cosmetics, but margins declined due to lower volumes, unfavorable mix and resin timing.
• Closures growth and costs — Strong beverage dispensing demand and new closure innovations drove sales, but margins were pressured by costs from new production lines and maintenance.

Aptar said second-quarter sales rose 6% and beat analyst expectations, helped by strength in consumer healthcare and injectables.

The company also said adjusted EPS for Q2 beat analyst expectations.